Carl Zeiss Meditec AG : Carl Zeiss Meditec records positive first quarter
Carl Zeiss Meditec AG /
Carl Zeiss Meditec AG : Carl Zeiss Meditec records positive first quarter
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec records positive first quarter
Revenue up four per cent, Microsurgery and Surgical Ophthalmology are strong
Irrespective of the difficult underlying global economic conditions, Carl Zeiss
Meditec AG closed the first quarter of financial year 2012/2013 with solid
earnings. The medical technology company's revenues were up by four per cent to
EUR 219.0m compared to the same quarter of the previous year; profitability and
earnings per share were also up.
JENA, 14 February 2013
In the first three months of the new financial year, the company recorded
revenues of EUR 219.0m (previous year: EUR 210.3m) and EBIT of EUR 31.2m
(previous year: EUR 28.3m). The EBIT margin improved from 13.4 per cent to 14.3
per cent; earnings per share increased compared to the same quarter of the
previous year from EUR 0.21 to EUR 0.29. The strategic business units exhibited
very different performance.
"Our positive overall growth is due, in particular, to the balanced and broad
footing of our business," commented Dr. Ludwin Monz, Carl Zeiss Meditec AG's
President and CEO. "In view of the reserved economic growth in many global
markets, the investments we have made in Asia are really paying off now."
Revenue by business unit
The Microsurgery strategic business unit (SBU) continued to be profitable and
displayed strong growth in the first quarter. Its revenues were up by 10.3 per
cent.
In contrast, revenues in the Ophthalmic Systems SBU were down by 6.9 per cent
with a positive contribution to earnings. As a result of a comprehensive change
of models at the end of the year, revenues for Optical Coherence Tomography
(OCT) decreased. At the same time, a higher level of competition was
increasingly noticeable in some segments of this business unit.
Revenue in the Surgical Ophthalmology SBU grew by 21.2 per cent. In particular,
a new product line for premium intraocular lenses contributed to the positive
development.
Revenue by region
In the EMEA region (Europe, Middle East, Africa) revenues were up by 1.2 per
cent with continued, highly non-uniform growth. Germany has continued to be the
main sales driver and enjoyed positive growth; the Russian market also proved
its continued strength, whereas the most of the other countries recorded
reserved or negative growth.
Performance in the Americas region was weak during the quarter. Excellent growth
rates in South America were counteracted by negative figures on the US market.
Once again, the APAC (Asia/Pacific) region recorded substantially double-digit
growth of 14.1 per cent. China, Japan and Australia made particularly strong
contributions to this growth.
In the words of Ludwin Monz, Carl Zeiss Meditec is, on the whole, positioned
robustly enough to also deal well with a weaker global economy. "A slower pace
of growth will also be reflected in our business over the longer term. However,
as things stand today, we are sticking to our targets through to 2015."
Revenue by strategic business unit
+----------------------+------------------+------------------+-----------------+
|Figures in € '000 |3 Months 2011/2012|3 Months 2012/2013|Change from |
| | | |previous year |
+----------------------+------------------+------------------+-----------------+
|Ophthalmic Systems |90,700 |84,421 |- 6.9% |
+----------------------+------------------+------------------+-----------------+
|Surgical Ophthalmology|24,325 |29,472 |+ 21.2% |
+----------------------+------------------+------------------+-----------------+
|Microsurgery |95,316 |105,106 |+ 10.3% |
+----------------------+------------------+------------------+-----------------+
Revenue by region
+-------------------+------------------+------------------+--------------------+
|Figures in € '000 |3 Months 2011/2012|3 Months 2012/2013|Change from previous|
| | | |year |
+-------------------+------------------+------------------+--------------------+
|EMEA |75,271Â |76,209 |+ 1.2% |
+-------------------+------------------+------------------+--------------------+
|Americas |73,897 |72,973 |- 1.3% |
+-------------------+------------------+------------------+--------------------+
|Asia/Pacific region|61,173 |69,817 |+ 14.1% |
+-------------------+------------------+------------------+--------------------+
Press contacts:
Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG
Phone 03641 220-331, E-Mail: press.meditec@zeiss.com
Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone 03641 220-106, E-Mail: investors.meditec@zeiss.com
www.meditec.zeiss.de/presse
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the
German stock exchange, is one of the world's leading medical technology
companies. The company supplies innovative technologies and application-oriented
solutions designed to help doctors improve the quality of life of their
patients. It provides complete packages of solutions for the diagnosis and
treatment of eye diseases, including implants and consumable materials. The
company creates innovative visualization solutions in the field of microsurgery.
The medical technology portfolio of Carl Zeiss Meditec is rounded off by
promising, future-oriented technologies such as intraoperative radiotherapy. In
financial year 2011/2012 (ended 30 September) the Group's more than 2,400
employees generated revenue of almost € 862 million. The head office of Carl
Zeiss Meditec is in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the USA, Japan, Spain and France. The Center for Research
and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations
Center for Research and Development in Shanghai, China, strengthen the Company's
presence in these rapidly developing economies. Around 35 percent of Carl Zeiss
Meditec shares are in free float. The remaining approx. 65 percent are held by
Carl Zeiss AG, one of the world's leading groups in the optical and
optoelectronic industries.
Fore more than 160 years Carl Zeiss has been contributing to the progress of
technology on the markets for Industrial Solutions, Research Solutions, Medical
Technology and Consumer Optics, improving the quality of life for many people.
Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.
For more information visit our website at: www.meditec.zeiss.de
Â
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1678121]
